File(s) under permanent embargo
Safety of ceasing aspirin used without a clinical indication after age 70 years: a subgroup analysis of the ASPREE randomized trial
journal contribution
posted on 2023-05-22, 01:31 authored by Mark NelsonMark Nelson, Polekhina, G, Reid, CM, Tonkin, AM, Murray, AM, Kirpach, B, Ernst, ME, Lockery, JE, Shah, RC, Stocks, N, Orchard, SG, Zhen ZhouZhen ZhouBackground: The ASPREE (ASPirin in Reducing Events in the Elderly) trial was a randomized, double-blind, placebocontrolled primary prevention trial of aspirin in 19114 communitydwelling persons aged 70 years and older (≥65 years in U.S. racial minorities). The results of the trial demonstrated that aspirin had no benefit for disability-free survival, prevention of cardiovascular disease events, or prevention of incident cancer, and increased risk for major bleeding and all-cause mortality (1–3). These findings were interpreted by some as being relevant only to aspirin initiation and not aspirin discontinuation (4). The availability of evidence to inform the risks (for example, forgone cardiovascular protection) and benefits (for example, decreased risk for major hemorrhage) from aspirin cessation among older adults is timely, given updated guideline recommendations regarding aspirin use and clinical uncertainty (5).
Objective: To investigate the effect of aspirin cessation versus continuation on disability-free survival and other clinical outcomes in a post hoc analysis of ASPREE participants who were regularly taking aspirin before trial enrollment.
History
Publication title
Annals of Internal MedicineVolume
175Issue
5Pagination
1-4ISSN
0003-4819Department/School
Tasmanian School of MedicinePublisher
Amer Coll PhysiciansPlace of publication
Independence Mall West 6Th And Race St, Philadelphia, USA, Pa, 19106-1572Rights statement
Copyright 2022 American College of PhysiciansRepository Status
- Restricted